ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

nelitolimod

Also written as “SD-101”, “SD-101 Dermal Cream (6%)” and “SD-101-6.0 cream”.

Its studies are mostly in Epidermolysis Bullosa · Carcinoma, Hepatocellular · Uveal Melanoma · Melanoma · Lymphoma, B-Cell, led by 5 companies.

Drug pageNelitolimod: every studyMany companies study it; this page follows only the 14 they lead. All 25 studies, academic ones too, with its approvals and label.
Furthest: phase 3, since Feb 13, 201514 company-led studies, 3 open or runningNext primary completion: May 17, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BioMarin Pharmaceuticalits history only40 open or runningphase 3since Feb 13, 2015Dec 12, 2013none ahead
Sanofiits history only40 open or runningphase 2since Oct 13, 2014Jan 11, 2008none ahead
TriSalus Life Sciencesits history only31 open or runningphase 2since Jan 21, 2022Jun 2, 2021Sep 2027phase 1 · NCT05607953
Paradigm Therapeutics22 open or runningphase 3since Mar 4, 2026Mar 4, 2026May 17, 2027phase 3 · NCT07482787
Merckits history only10 open or runningphase 1since Apr 4, 2016Apr 4, 2016none ahead

Also a collaborator on its studies: Synteract and PPD DEVELOPMENT, LP.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Paradigm Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 11, 2024Named nelitolimodINNProposed as its International Nonproprietary Name in WHO's List 131 · before, SD-101
  2. Mar 4, 2026First studies: 2 phase 3 studies in Epidermolysis BullosaFirst studyNCT07482813, NCT07482787

Ahead

  1. May 17, 2027Primary completion: phase 3 study in Epidermolysis BullosaNCT07482787
  2. Sep 19, 2027Primary completion: phase 3 study in Epidermolysis BullosaNCT07482813

TargetBeta

TLR9 →read by rule
“A class C CpG-oligodeoxynucleotide (ODN) agonist of toll-like receptor 9 (TLR9), with immunostimulatory, immunoadjuvant and antineoplastic activities”NCIt, by rule

Studies

All 2 Paradigm Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07482813Epidermolysis Bullosa3Not yet recruitingSep 19, 202780
NCT07482787Epidermolysis Bullosa · United States3RecruitingMay 17, 202780

How it is read

Names in the registry

  • “SD-101”, 7 entries
  • “SD-101 Dermal Cream (6%)”, 3 entries
  • “SD-101-6.0 cream”, 2 entries
  • “SD-101(1)”, 1 entry
  • “SD-101(2)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.